The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

• Status: Completed
• Trial end date: 1994-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts <= 100 cells/mm3.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Clarithromycin

Criteria

Inclusion Criteria

Patients must have:

• HIV infection.

• CD4 count <= 100 cells/mm3.

• No evidence of MAC.

• Life expectancy of at least 6 months.

Exclusion Criteria

Concurrent Medication:

Excluded:

• Certain restricted drugs (details not available).

Patients with the following prior conditions are excluded:

History of allergy or hypersensitivity to macrolides. Active substance abuse or other conditions that would affect study compliance.